[O10] Oral Session 10　臓器横断プログラム
【E】

[O10-1] NTRK融合遺伝子陽性の成人患者におけるラロトレクチニブの有効性と安全性

^○田原 信¹, Brose Marcia S.², Shen Lin³, Tan Daniel S.W⁴, Kummar Shivaani⁵, Lin Jessica J.^6,7, McDermott Ray⁸, Berlin Jordan⁹, Lassen Ulrik N.¹⁰, Leyvraz Serge¹¹, Patel Jyoti D.¹², Norenberg Ricarda¹³, Dima Laura¹⁴, Brega Nicoletta¹⁵, Hong David S.¹⁶, Drilon Alexander^17,18 (1.国立がん研究センター東病院 頭頸部内科, 2.Abramson Cancer Center of the University of Pennsylvania School of Medicine, Philadelphia, PA, USA, 3.Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, China, 4.Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore, 5.Oregon Health & Science University, Portland, OR, USA, 6.Department of Medicine, Massachusetts General Hospital, Boston, MA USA, 7.Harvard Medical School, Boston, MA USA., 8.St Vincent's University Hospital and Cancer Trials Ireland, Dublin, Ireland, 9.Vanderbilt University Medical Center, Nashville, TN, USA, 10.Department of Oncology, Rigshospitalet, Copenhagen, Denmark, 11.Charité – Universitätsmedizin Berlin, Berlin, Germany, 12.Northwestern University, Chicago, IL, USA, 13.Chrestos Concept GmbH & Co. KG, Essen, Germany, 14.Bayer HealthCare Pharmaceuticals, Inc., Basel, Switzerland, 15.Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA, 16.The University of Texas MD Anderson Cancer Center, Houston, TX, USA, 17.Memorial Sloan Kettering Cancer Center, New York, NY, USA, 18.Weill Cornell Medical College, New York, NY, USA)